ReviewAntibiotics (Basel, Switzerland)2021
Clinical Status of Efflux Resistance Mechanisms in Gram-Negative Bacteria.
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Role of MexAB-OprM and MexXY-OprM efflux pumps in carbapenem-resistant Pseudomonas aeruginosa from burn wounds.Molecular biology reports · 2026Article
- Genetic variants of AcrAB and OqxAB and the impact of efflux pump inhibition on ciprofloxacin and amikacin resistance in clinical isolates of Klebsiella pneumoniae from Lima, Peru.BMC microbiology · 2026Article
- Effect of sub-inhibitory tigecycline (½-MIC) on AcrAB-TolC andFrontiers in cellular and infection microbiology · 2026Article
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance.Frontiers in microbiology · 2026Review
- The occurrences ofIranian journal of microbiology · 2025Article
- Efflux-Mediated Resistance inAntibiotics (Basel, Switzerland) · 2025Review
- Zinc Phosphate Microparticles against Nosocomial and Oral Bacteria: Synthesis, Analytical Characterization, and Biocompatibility.ACS omega · 2025Article
- Public Health Risk ofPathogens (Basel, Switzerland) · 2025Article
- Antimicrobial Action Mechanisms of Natural Compounds Isolated from Endophytic Microorganisms.Antibiotics (Basel, Switzerland) · 2024Review
- Maribacter halichondriae sp. nov., isolated from the marine sponge Halichondria panicea, displays features of a sponge-associated life style.Antonie van Leeuwenhoek · 2024Article
- Antimicrobial resistance genes harbored in invasiveFrontiers in cellular and infection microbiology · 2024Article
- Repurposing approved drugs as potential efflux pump inhibitors in multidrug-resistantFuture microbiology · 2024Article
- High Prevalence of Antimicrobial Resistance Genes in Multidrug-Resistant Extended-Spectrum Beta-Lactamase-ProducingAdvanced biomedical research · 2024Article
- Di-berberine conjugates as chemical probes of Pseudomonas aeruginosa MexXY-OprM efflux function and inhibition.npj antimicrobials and resistance · 2023Article
- Di-berberine conjugates as chemical probes ofbioRxiv : the preprint server for biology · 2023Article
- Antimicrobial Resistance in Romania: Updates on Gram-Negative ESCAPE Pathogens in the Clinical, Veterinary, and Aquatic Sectors.International journal of molecular sciences · 2023Review
- Targeting the Holy Triangle of Quorum Sensing, Biofilm Formation, and Antibiotic Resistance in Pathogenic Bacteria.Microorganisms · 2022Review
- Evasion of Antimicrobial Activity inInternational journal of molecular sciences · 2022Review
- The Structural and Functional Study of Efflux Pumps Belonging to the RND Transporters Family from Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic efflux is a mechanism that is well-documented in the phenotype of multidrug resistance in bacteria. Efflux is considered as an early facilitating mechanism in the bacterial adaptation face to the concentration of antibiotics at the infectious site, which is involved in the acquirement of complementary efficient mechanisms, such as enzymatic resistance or target mutation. Various efflux pumps have been described in the Gram-negative bacteria most often encountered in infectious diseases and, in healthcare-associated infections. Some are more often involved than others and expel virtually all families of antibiotics and antibacterials. Numerous studies report the contribution of these pumps in resistant strains previously identified from their phenotypes. The authors characterize the pumps involved, the facilitating antibiotics and those mainly concerned by the efflux. However, today no study describes a process for the real-time quantification of efflux in resistant clinical strains. It is currently necessary to have at hospital level a reliable and easy method to quantify the efflux in routine and contribute to a rational choice of antibiotics. This review provides a recent overview of the prevalence of the main efflux pumps observed in clinical practice and provides an idea of the prevalence of this mechanism in the multidrug resistant Gram-negative bacteria. The development of a routine diagnostic tool is now an emergency need for the proper application of current recommendations regarding a rational use of antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.